Clinical Trial: A Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors

U.S., Nov. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07923214) titled 'A Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors' on Oct. 27.

Brief Summary: This is a Phase I, open-label, multi-center study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of CG-7321 capsules as monotherapy or in combination with fulvestrant in subjects with advanced solid tumors.

The study consists of:

* Part Ia (Monotherapy): Dose escalation (accelerated titration followed by 3+3 design) from 2mg to 50mg twice daily (BID), plus dose expansion cohorts in advanced solid tumors including HR+/HER2- breast cancer, ovarian cancer, gastric cancer, and other t...